Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06937593 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954

A Phase 1 study of Healthy, sponsored by Visterra.

Active
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT06937593 is a Phase 1 study of Healthy that is active but no longer recruiting, run by Visterra. The registered enrollment target is 24 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06937593, a Phase 1 study of Healthy, is active but no longer recruiting, sponsored by Visterra.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple doses of VIS954 compared with placebo in healthy adult participants.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG VIS954

Study Locations (1)

California

  • Anaheim Clinical Trials, LLC - Anaheim

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-03-13
Est. Completion 2026-02-13
Phase Phase 1

Sponsor

Visterra

4 total trials

What the Registry Record Tells You About NCT06937593

The ClinicalTrials.gov registry entry for NCT06937593 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is Visterra, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06937593 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06937593 about?

NCT06937593 is a clinical study titled "A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954". The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple doses of VIS954 compared with placebo in healthy adult participants.

What is the current status of trial NCT06937593?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-03-13. Estimated completion is 2026-02-13.

What conditions does trial NCT06937593 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT06937593?

The interventions under investigation include: Placebo (DRUG), VIS954 (DRUG).

Who is sponsoring clinical trial NCT06937593?

This trial is sponsored by Visterra, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06937593 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.